The short answer
Retatrutide is the INN, LY3437943 the development code, and reta an informal abbreviation. The codes most easily confused with it are Lilly's own: LY3298176 is tirzepatide and LY3502970 is orforglipron.
Key facts
- INN
- Retatrutide
- Development code
- LY3437943
- Informal
- Reta
- Easily confused
- LY3298176: tirzepatide
- Also confusable
- LY3502970: orforglipron
- Finds research
- Retatrutide, LY3437943
- Finds market content
- Reta
The three names and what each returns
Retatrutide finds the peer-reviewed literature and the trial registrations. LY3437943 finds the same plus earlier development-era records, including the Coskun discovery paper's title. Reta finds forum and commercial content almost exclusively, because no researcher uses it.
The confusion that actually causes errors
Not spelling, but the Lilly codes. LY3437943, LY3298176 and LY3502970 are retatrutide, tirzepatide and orforglipron respectively. Three similar codes, one company, three compounds at different regulatory stages. This library found two real errors from exactly this: a tirzepatide PubChem record cited as retatrutide, and orforglipron's ATTAIN-1 trial labelled as retatrutide's TRIUMPH-1.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why the trial names are also confusable
TRIUMPH is retatrutide's Phase 3 programme; SURMOUNT is tirzepatide's; ACHIEVE and ATTAIN are orforglipron's. All are Lilly programmes with similar naming conventions running concurrently. Checking which compound a registration names, rather than trusting the programme name, is the only reliable approach.
Hyphenation and case
LY3437943, LY-3437943 and LY 3437943 all appear and signal nothing. Retatrutide is not hyphenated. None of these variations carries information about the compound.
The practical rule
Verify the compound named in any record before citing it. A number that looks right is not evidence that it is right. Both of this library's errors involved identifiers that appeared entirely plausible, from the correct company, in the correct format, pointing at the wrong molecule.
Quick reference
| Code | Compound | Status |
|---|---|---|
| LY3437943 | Retatrutide | Investigational |
| LY3298176 | Tirzepatide | Approved |
| LY3502970 | Orforglipron | Approved (UK, Aug 2026) |
Frequently asked questions
Is 'reta' used in research?
No. It appears in commercial and forum content. Papers use retatrutide or LY3437943.
What is the most common source of confusion?
Lilly's three similar development codes: LY3437943, LY3298176 and LY3502970 are three different compounds at three different regulatory stages.
How do I avoid citing the wrong one?
Check the compound named in the record itself. A plausible-looking identifier from the right company can still point at the wrong molecule.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedCoskun T et al., LY3437943. Cell Metab 2022 (PMID 35985340)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Tirzepatide, LY3298176 (CID 166567236)pubchem.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov: ATTAIN-1, orforglipron (NCT05869903)clinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066). Retatrutide Phase 3 obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-2 (NCT05929079). Retatrutide in type 2 diabetesclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-3 (NCT05882045). Retatrutide + established CVDclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-4 (NCT05931367). Retatrutide once weeklyclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-5 (NCT06662383). Retatrutide vs tirzepatideclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-6 (NCT06859268). Maintenance of weight reductionclinicaltrials.gov
- PubMedJastreboff AM et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM 2023 (PMID 37366315)pubmed.ncbi.nlm.nih.gov
- PubMedRosenstock J et al., Retatrutide for people with type 2 diabetes. Lancet 2023 (PMID 37385280)pubmed.ncbi.nlm.nih.gov
- DrugBankDrugBank · Retatrutide (DB18435)go.drugbank.com
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More Retatrutide Research articles
- The History of RetatrutideFrom the 2022 Cell Metabolism discovery paper through Phase 2 in NEJM to the TRIUMPH Phase 3 readouts of 2026 and a signalled FDA filing.
- Retatrutide Clinical Trial Timeline: Phase 1 to TRIUMPHRetatrutide trial timeline: Phase 1 in 2020, Phase 2 in NEJM 2023, Phase 3 TRIUMPH readouts December 2025 to July 2026, FDA filing signalled for Q1 2027.
- Who Develops Retatrutide?Eli Lilly, under the code LY3437943. Why that matters for reading trial data, and why no licensed retatrutide product exists.
- Retatrutide Half-Life: Where It Comes FromThe C20 diacid binds albumin reversibly, supporting once-weekly trial dosing. Why chain length sets duration across the whole incretin family.
- Retatrutide Chemical Identity: What Can Actually Be VerifiedRetatrutide has no findable PubChem record. What that means for its reported CAS and molecular weight, and why one widely cited identifier is tirzepatide's.